Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
Herbert Smith Freehills Kramer advises The Riverside Company on its sale of Smartways
HSF Kramer is pleased to be advising the shareholders of Smartways, including The Riverside Company, on the sale of that business to United Parcel …
New report highlights challenges, risks, and opportunities in the global financial services landscape – and how regulators and firms are responding
A new report from Herbert Smith Freehills Kramer's global Financial Services Regulatory (FSR) team analyses the increasingly unpredictable, changing …
Herbert Smith Freehills Kramer advises global asset manager on sale of C3 and Pedersen businesses to InfraRed Capital Partners
Herbert Smith Freehills Kramer (HSF Kramer) has advised a global asset manager on the Australian aspects of its sale of C3 Limited (C3), a New …
Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead